
Diranersen shows 38% clinical decline slowing at 2 years in early Alzheimer's, boosting hope for treatment.
Biogen's investigational drug diranersen demonstrated a 38% slowing of clinical decline at two years in early Alzheimer's patients, with the 60 mg twice-yearly dose showing the strongest benefits across multiple cognitive and functional measures. Pre...

